PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine whether combined treatment with
phosphodiesterase-4 (PDE-4) inhibitor roflumilast and metformin is more effective than
metformin as monotherapy in the treatment of obese women with polycystic ovary syndrome
(PCOS) who had been previously poor responders regarding weight reduction on metformin
monotherapy. The investigators anticipated greater changes in body weight in patients on
combined treatment than in those on monotherapy with metformin.